Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study

References

• Lopez-Garcia MA, Feria-Romero IA, Serrano H, et al. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacol Rep. 2017;69(3):504–511. doi:10.1016/j.pharep.2017.01.00728343093
   PubMed Web of Science ®Google Scholar
• Bhalla D, Lotfalinezhad E, Timalsina U, et al. A comprehensive review of epilepsy in the Arab world. Seizure. 2016;34:54–59.26724591
   PubMed Web of Science ®Google Scholar
• Bicalho MA, Sukys-Claudino L, Guarnieri R, Lin K, Walz R. Socio-demographic and clinical characteristics of Brazilian patients with epilepsy who drive and their association with traffic accidents. Epilepsy Behav. 2012;24(2):216–220.22572537
   PubMed Web of Science ®Google Scholar
• Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015;5(6).
   PubMed Web of Science ®Google Scholar
• Winkler AS, Kerschbaumsteiner K, Stelzhammer B, Meindl M, Kaaya J, Schmutzhard E. Prevalence, incidence, and clinical characteristics of epilepsy–a community-based door-to-door study in northern Tanzania. Epilepsia. 2009;50(10):2310–2313.19583783
   PubMed Web of Science ®Google Scholar
• Cohen N. Pharmacogenomics and Personalized Medicine. Totowa, NJ: Humana Press; 2008:299.
   Google Scholar
• Wang J, Lin ZJ, Liu L, et al. Epilepsy-associated genes. Seizure. 2017;44:11–20.28007376
   PubMed Web of Science ®Google Scholar
• Allen NM, Conroy J, Shahwan A, et al. Unexplained early onset epileptic encephalopathy: exome screening and phenotype expansion. Epilepsia. 2016;57(1):e12–e17.26648591
   PubMed Web of Science ®Google Scholar
• Henning O, Nakken KO. [New epilepsy classification]. Tidsskr Nor Laegeforen. 2017;137:23–24.
   Google Scholar
• Genç F, Kutlu G, Gomceli YB, Inan LE. Demographic and clinical findings of patients with refractory epilepsy followed by the epilepsy department of the Ankara education and research hospital. Epilepsi. 2013;19(2):79–85. doi:10.5505/epilepsi.2013.68552
   Google Scholar
• Piperidou C, Karlovasitou A, Triantafyllou N, et al. Association of demographic, clinical and treatment variables with quality of life of patients with epilepsy in Greece. Qual Life Res. 2008;17(7):987–996. doi:10.1007/s11136-008-9375-918663600
   PubMed Web of Science ®Google Scholar
• Dasgupta A. Handbook of Drug Monitoring Methods. Totowa, N.J.: Humana Press; 2008:211–223.
   Google Scholar
• Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neurosci Lett. 2018;667:27–39. doi:10.1016/j.neulet.2017.01.01428082152
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Martinez-Bouza R, Carril JC, et al. Genomics and pharmacogenomics of brain disorders. Curr Pharm Biotechnol. 2012;13(5):674–725.22122480
   PubMed Web of Science ®Google Scholar
• Emich-Widera E, Likus W, Kazek B, et al. CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. Biomed Res Int. 2013;2013:526837. doi:10.1155/2013/52683723984379
   PubMed Web of Science ®Google Scholar
• Kartal A. Knowledge of, perceptions of, attitudes and practices regarding epilepsy among medical students in Turkey. Epilepsy Behav. 2016;58:115–118. doi:10.1016/j.yebeh.2016.02.04227070860
   PubMed Web of Science ®Google Scholar
• Chen HF, Tsai YF, Hsi MS, Chen JC. Factors affecting quality of life in adults with epilepsy in Taiwan: a cross-sectional, correlational study. Epilepsy Behav. 2016;58:26–32. doi:10.1016/j.yebeh.2016.02.01927002941
   PubMed Web of Science ®Google Scholar
• Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav. 2011;21(1):27–30. doi:10.1016/j.yebeh.2011.02.01521493161
   PubMed Web of Science ®Google Scholar
• Yun W, Zhang F, Hu C, et al. Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Res. 2013;107(3):231–237.24125961
   PubMed Web of Science ®Google Scholar
• Wang P, Yin T, Ma HY, et al. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy Res. 2015;117:52–57.26421491
   PubMed Web of Science ®Google Scholar
• Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 2014;15(15):1867–1879.25495409
   PubMed Web of Science ®Google Scholar
• Laity JH, Lee BM, Wright PE. Zinc finger proteins: new insights into structural and functional diversity. Curr Opin Struc Biol. 2001;11(1):39–46.
   PubMed Web of Science ®Google Scholar
• Isalan M; Zinc Fingers. Encyclopedia of Biological Chemistry. Elsevier Inc; 2013:575–579.
   Google Scholar
• Szczepankiewicz A, Breborowicz A, Sobkowiak P, Kramer L, Popiel A. [Association of A/T polymorphism of the CHRM2 gene with bronchodilator response to ipratropium bromide in asthmatic children]. Pneumonol Alergol Pol. 2009;77(1):5–10.19308904
   PubMedGoogle Scholar
• Gosso FM, de Geus EJ, Polderman TJ, Boomsma DI, Posthuma D, Heutink P. Exploring the functional role of the CHRM2 gene in human cognition: results from a dense genotyping and brain expression study. BMC Med Genet. 2007;8:66.17996044
   PubMed Web of Science ®Google Scholar
• Gosso MF, van Belzen M, de Geus EJ, et al. Association between the CHRM2 gene and intelligence in a sample of 304 Dutch families. Genes Brain Behav. 2006;5(8):577–584.17081262
   PubMed Web of Science ®Google Scholar
• AL-Eitan LN, Al-Dalalah IM, Elshammari AK, Khreisat WH, Almasri AY. The impact of potassium channel gene polymorphisms on antiepileptic drug responsiveness in arab patients with epilepsy. J Pers Med. 2018;8(4).
   Web of Science ®Google Scholar
• Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005;95(3):221–227.16077740
   PubMed Web of Science ®Google Scholar
• AL-Eitan LN, Al-Dalalah IM, Mustafa MM, et al. Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients. Pharmgenomics Pers Med. 2019;12:87–95.31354331
   PubMed Web of Science ®Google Scholar
• Dunn DW, Austin JK. Behavioral issues in pediatric epilepsy. Neurology. 1999;53(5 Suppl 2):S96–S100.10496240
   PubMed Web of Science ®Google Scholar
• Tamashiro EY, Felipe CR, Genvigir FDV, et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. Drug Metab Pers Ther. 2017;32(2):89–95.28593920
   PubMedGoogle Scholar
• Cacabelos R. Pharmacogenomics of Central Nervous System (CNS) drugs. Drug Dev Res. 2012;73(8):461–476.
   Web of Science ®Google Scholar
• Milovanovic DD, Radosavljevic I, Radovanovic M, et al. CYP3A5 polymorphism in serbian paediatric epileptic patients on carbamazepine treatment. Serbian J Exp Clin Res. 2015;16(2):93–99.
   Google Scholar
• Magiorkinis E, Diamantis A, Sidiropoulou K, Panteliadis C. Highights in the history of epilepsy: the last 200 years. Epilepsy Res Treat. 2014;2014:582039.25210626
   PubMedGoogle Scholar
• Thorn CF, Leckband SG, Kelsoe J, et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics. 2011;21(12):906–910.21738081
   PubMed Web of Science ®Google Scholar
• Esterhuizen AI, Carvill GL, Ramesar RS, et al. Clinical application of epilepsy genetics in Africa: is now the time? Front Neurol. 2018;9:276.29770117
   PubMed Web of Science ®Google Scholar
• Zhang X, Men T, Liu H, Li X, Wang J, Lv J. Genetic risk factors for post-transplantation diabetes mellitus in Chinese Han renal allograft recipients treated with tacrolimus. Transpl Immunol. 2018;49:39–42.29665413
   PubMed Web of Science ®Google Scholar
• Scarr E. Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets. CNS Neurosci Ther. 2012;18(5):369–379.22070219
   PubMed Web of Science ®Google Scholar